Loading…
MODERATEChannel News AsiaUnverifiedUnpublished
Fact-check: The Channel News Asia article accurately summarizes a March 2026 medRxiv preprint study estimating generic semaglutide (Ozempic/Wegovy) manufacturing costs as low as US$3 per month once patents expire in many countries. This claim is supported by real-time X posts from reputable accounts like @business (Bloomberg), @statnews, and @pharmalot, as well as coverage from Guardian, Bloomberg, and STAT News, with no contradictions found.
Anti-obesity treatment could cost as little as US$3 per month: study
public-healthobesity-treatmentglobal-healthweight-management
A recent study has found that an anti-obesity treatment could be made available for as low as US$3 per month, potentially increasing access to effective weight management options for individuals worldwide. The treatment's affordability could have significant implications for public health. Further research is needed to confirm the findings and ensure the treatment's safety and efficacy. The study's results may lead to more affordable and accessible obesity treatments in the future.